Exclusive License Agreement
Arkema has granted SEQENS an exclusive technology license to manufacture PEKK for long-term medical implantable applications. This agreement marks a significant step in their 15-year collaboration, combining Arkema's expertise in PEKK technology with SEQENS' proficiency in polymer production for the pharmaceutical and life sciences markets.
PEKK Applications
PEKK, a high-performance polymer used in demanding markets like aerospace, is commercialized by Arkema under the Kepstan® trademark. SEQENS has developed IMPEKK materials specifically for long-term medical implantable applications, which will be distributed globally through a network of partners, including manufacturers and 3D printing companies.
Commitment to Innovation
SEQENS is committed to delivering top-tier solutions, leveraging its expertise in complex chemistry and polymer synthesis. Projects are already underway in Europe, the USA, and Asia, highlighting the global reach and impact of this partnership.
